The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Promising strategies to optimize CAR-T therapy in ALL
Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, discusses strategies to optimize CAR-T therapy in acute lymphoblastic leukemia (ALL), drawing focus on the potential role of dual-targeting approaches and the importance of improving persistence. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
